Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 3/20 | 0.58 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.58 |
| ▸ | ELANE | P08246 | 10/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.40 |
| ▸ | PER2 | O15055 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784936 | 0.86 | CPT1A (0.68) | CPT1ACPT1BMCL1PER2CNR1 | |
| SCHEMBL3789008 | 0.85 | CPT1A (0.61) | CPT1ACPT1BMCL1PER2CNR1 | |
| SCHEMBL959127 | 0.83 | CPT1A (0.42) | CPT1ACPT1BELANEMCL1F2RL3 | |
| SCHEMBL962070 | 0.83 | ELANE (0.51) | ELANEMCL1KDM4EMAPTPKM | |
| Hydrochloric Acid SCHEMBL959126 | 0.82 | CPT1A (0.41) | CPT1ACPT1BELANEMCL1F2RL3 | |
| SCHEMBL961017 | 0.81 | ELANE (0.46) | CPT1ACPT1BELANEMCL1KDM4E | |
| SCHEMBL958863 | 0.80 | CPT1A (0.72) | CPT1ACPT1BCNR1 | |
| SCHEMBL958866 | 0.79 | CPT1A (0.54) | CPT1ACPT1BMAPT | |
| SCHEMBL959272 | 0.79 | CPT1A (0.41) | CPT1ACPT1BELANEMCL1F2RL3 | |
| SCHEMBL960379 | 0.78 | CPT1A (0.74) | CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071628-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | ACKERMANN JEAN | 2011-01-20 | — | — | US | disclosed |
| US-7858645-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2079703-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052898-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103182-A1 | INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103182-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | CPT1A 1/4885CPT1B 2/4885ELANE 1677/4885 |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | CPT1A 1/4885CPT1B 2/4885ELANE 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.